Novo's Human Growth Hormone Patent Ruled Invalid, Unenforceable

Law360, New York (August 6, 2004, 12:00 AM EDT) -- A federal district court has found Danish drug maker Novo Nordisk's patent for recombinant human growth hormone invalid and unenforceable due to inequitable conduct.

The decision by the U.S. District Court for the District of Delaware deals a blow to the world’s largest insulin maker’s bid to block Israeli generics maker Teva Pharmaceuticals Industries Ltd. and Savient Pharmaceuticals Inc. from selling human growth hormone in the U.S.

The judge said a patent owned by Novo was invalid because of Novo's errors in the application process before...
To view the full article, register now.